Characteristics of patients with B-cell malignancies who received tixagevimab-cilgavimab
| Patient variable . | SARS-CoV-2 negative (n =224) . | SARS-CoV-2 positive (n = 27) . |
|---|---|---|
| Median age, y (range) | 66 (18-91) | 67 (22-80) |
| ≥65 y, n (%) | 119 (53) | 10 (47) |
| Sex, n (%) | ||
| Male | 132 (59) | 18 (67) |
| Female | 92 (41) | 9 (33) |
| Diagnosis, n (%) | ||
| B-ALL | 8 (4) | 1 (4) |
| CLL | 52 (23) | 6 (22) |
| DLBCL | 48 (22) | 6 (22) |
| FL | 16 (7) | 3 (11) |
| MCL | 18 (8) | 3 (11) |
| MZL | 5 (3) | 0 (0) |
| MM | 32 (14) | 2 (7) |
| PCNSL | 4 (2) | 1 (4) |
| WM | 10 (4) | 1 (4) |
| Other | 31 (14) | 4 (15) |
| Performance status (ECOG), n (%) | ||
| 0-1 | 194 (87) | 23 (85) |
| 2 or higher | 30 (13) | 4 (15) |
| Median prior lines of therapy (range) | 1 (0-14) | 1 (1-6) |
| Prior hematopoietic stem cell transplant, n (%) | ||
| Allogeneic | 12 (5) | 2 (7) |
| Autologous | 43 (19) | 3 (11) |
| Prior CAR T-cell therapy, n (%) | ||
| NHL | 13 (6) | 0 (0) |
| MM | 6 (3) | 0 (0) |
| SARS-CoV-2 infection prior to tixagevimab-cilgavimab, n (%) | 70 (31) | 5 (19) |
| Median prior SARS-CoV-2 vaccines, n (range) | 3 (0-5) | 3 (0-5) |
| Patient variable . | SARS-CoV-2 negative (n =224) . | SARS-CoV-2 positive (n = 27) . |
|---|---|---|
| Median age, y (range) | 66 (18-91) | 67 (22-80) |
| ≥65 y, n (%) | 119 (53) | 10 (47) |
| Sex, n (%) | ||
| Male | 132 (59) | 18 (67) |
| Female | 92 (41) | 9 (33) |
| Diagnosis, n (%) | ||
| B-ALL | 8 (4) | 1 (4) |
| CLL | 52 (23) | 6 (22) |
| DLBCL | 48 (22) | 6 (22) |
| FL | 16 (7) | 3 (11) |
| MCL | 18 (8) | 3 (11) |
| MZL | 5 (3) | 0 (0) |
| MM | 32 (14) | 2 (7) |
| PCNSL | 4 (2) | 1 (4) |
| WM | 10 (4) | 1 (4) |
| Other | 31 (14) | 4 (15) |
| Performance status (ECOG), n (%) | ||
| 0-1 | 194 (87) | 23 (85) |
| 2 or higher | 30 (13) | 4 (15) |
| Median prior lines of therapy (range) | 1 (0-14) | 1 (1-6) |
| Prior hematopoietic stem cell transplant, n (%) | ||
| Allogeneic | 12 (5) | 2 (7) |
| Autologous | 43 (19) | 3 (11) |
| Prior CAR T-cell therapy, n (%) | ||
| NHL | 13 (6) | 0 (0) |
| MM | 6 (3) | 0 (0) |
| SARS-CoV-2 infection prior to tixagevimab-cilgavimab, n (%) | 70 (31) | 5 (19) |
| Median prior SARS-CoV-2 vaccines, n (range) | 3 (0-5) | 3 (0-5) |
B-ALL, B-cell acute lymphoblastic leukemia; DLBCL, diffuse large B-cell lymphoma; ECOG, Eastern Cooperative Performance Group; FL, follicular lymphoma; MCL, mantle cell lymphoma; MM, multiple myeloma; MZL, marginal zone lymphoma; NHL, non-Hodgkin lymphoma; PCNSL, primary central nervous system lymphoma; WM, Waldenström macroglobulinemia.